Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oritavancin in ABSSSI (SOLO I)
NCT01252719Phase 3Completed
- Sponsor
- Melinta Therapeutics
- Start
- Dec 2010
- Primary completion
- Oct 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oritavancin in acute bacterial skin and skin structure infection (ABSSSI) (2 arms), sponsored by Melinta Therapeutics. Primary endpoint: Cessation Of Spread Or Reduction In Size Of Baseline Lesion, Absence Of Fever, And No Rescue Antibiotic Medication At Early Clinical Evaluation (ECE). Started Dec 2010; status: completed.
02
Drugs
oritavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT01252719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01252719.